MILAN – The first biosimilar adalimumab appears in Italy for the treatment of adult severe chronic inflammatory diseases such as moderate to severe rheumatoid arthritis, psoriatic arthritis, severe active ankylosing spondylitis, moderate to severe Crohn's disease and moderate to severe severe ulcerative colitis. Amgen is also approved for the treatment of certain inflammatory children diseases: moderate and severe Crohn's disease (from 6 years), severe plaque psoriasis (from 4 years), arthritis associated with tendonitis inflammation (from 6 am years later) and polyarthritis Juvenile idiopathic arthritis (from 2 years).
"Biosimilators are an opportunity for a clinician because they present a profile of effectiveness and safety that can be compared to original biological products, but save resources, especially considering that in Italy the number of patients treated with biotechnology drugs is among the lowest in Europe and if we refer to the budgetary constraints of individual regions – declares Luigi Sinigaglia, director of the complex rheumatic structure, Traumatologic Orthopedic Specialist Center Gaetano Pini-CTO, Milan – Our biosimilar experiences are generally positive, especially in so-called naive patients who have never been treated with biological drugs before , and there is no reason not to use biosimilar in a patient who has indications for this particular medicine, but it is important to avoid continuous switching (switching) from one biosimilar to another for purely economic reasons. in the case of biosimilars, as in the case of initiators, the principle of therapeutic continuity must apply. '
For André Dahinden, President and CEO of Amgen Italia, "with biosimilar adalimumab, we are entering a new therapeutic area for Europe and Italy." This is our second biosimilar available in Italy, confirming the commitment of patients, clinicians and healthcare systems that combine innovation and sustainability " . ([email protected])
reserved reproduction ®